Psoriasis: what therapy actually involves

No, and that word does a lot of damage when it is heard as 'untreatable'. Psoriasis is a long-term immune-mediated condition that is controlled rather than eliminated, and for many people control now means skin that is clear or nearly so. The gap between 'incurable' and 'untreatable' has widened enormously since biologics arrived, and someone whose impression of psoriasis was formed fifteen years ago is working from an out-of-date picture.

You can manage scale and dryness with them, and that is genuinely worth doing — but you cannot treat the disease. In the United States the over-the-counter monograph permits only coal tar to carry a psoriasis indication at all, and nothing available without a prescription touches the immune signalling that drives it. Emollients and salicylic acid preparations make prescribed treatment work better by softening what sits on top of the plaque. That is a real contribution and it is not the same as treatment.

Not at all, in any way, by any route. Psoriasis is an immune-mediated disease, not an infection, and no amount of contact transmits it. This is worth stating plainly because it remains one of the most common misconceptions people with psoriasis encounter, and the social cost of it is a genuine part of the burden of the disease.

It may well be connected, and it is the single most important thing on this page to act on. Psoriatic arthritis affects a substantial minority of people with psoriasis, usually appearing after the skin disease, and it causes joint damage that does not reverse. Morning stiffness lasting more than half an hour, a whole finger or toe swelling, heel pain, or persistent low back stiffness are the patterns to report. Skin treatment can wait a few weeks; this should not.

Sunlight often does improve psoriasis, which is precisely why medical phototherapy exists — but a commercial sunbed is not a substitute for it. Medical narrow-band UVB delivers a specific, controlled wavelength at a measured dose with cumulative exposure tracked; a sunbed delivers a broad, largely UVA output aimed at tanning, with a well-established skin cancer risk and none of the dose control. If light helps your psoriasis, that is a good reason to ask about phototherapy rather than a reason to buy a course of sunbeds.

There is no good evidence that eliminating either helps psoriasis in people without coeliac disease, and restrictive diets carry their own costs. What does have support is less dramatic: not smoking, moderating alcohol, and — where relevant — weight management, which has reasonable evidence for improving both psoriasis and the response to some treatments. Those are unexciting recommendations, and they are the ones with something behind them.

Stress is a well-recognised trigger for flares, and it is not the cause. Psoriasis has a substantial genetic component and a specific immunological mechanism, neither of which is created by stress — but the relationship is real and it runs both ways, since having visible psoriasis is itself stressful. Managing stress is reasonable and worthwhile; being told the condition is caused by it is neither accurate nor fair.

Not necessarily, and this is one of the most useful things to know before an appointment. Extent gets measured, but guidance weighs site and impact alongside it. Scalp, face, palms, soles, nails and genital skin are all places where a small measured area justifies treatment that the same area on a back would not, because of what it costs you in walking, working, sleeping and being looked at. Palm and sole disease in particular is notoriously hard to shift with creams and is a recognised reason to consider light treatment or a tablet despite very little total skin being involved.

It depends entirely on the tier, and it is a fair question to ask while choosing between two options. Creams and light treatment need none. The older tablets each have something specific watched — blood counts and liver, or kidney function and blood pressure, or cholesterol — usually before starting and then at intervals. The newest tablets need considerably less. Injected treatments are screened for tuberculosis and hepatitis before the first dose and then need relatively little ongoing monitoring, which surprises people who assume the newest treatments must be the most closely watched.

This is one of the few places on this site where the answer is a flat no rather than a discussion. Oral corticosteroids do settle psoriasis quickly, and coming off them can tip it into a far more severe form — both of the emergencies described at the top of this page are recognised consequences of that withdrawal. It is why psoriasis is one of the inflammatory skin conditions where a short steroid course is generally avoided, and why a steroid taper prescribed for something else is worth mentioning to whoever manages your skin.

The recent arrivals are the interesting part here, which is unusual. Two non-steroid creams reached approval in 2022 and are used where steroids cannot be continued. A tablet acting on a single signalling enzyme followed, which matters to anyone who would rather not inject. An antibody aimed at the pustular form was approved for those flares and works within days, in a presentation that previously had nothing developed for it. Tablets aimed at the same targets as the injected drugs are in late-stage trials now. What none of this changes is the shape of this page: every one of them is prescribed.

Sharply bordered plaques with thick silvery scale, on elbows, knees, scalp or lower back — plus nail changes, which are the most useful confirming sign.

Plaque psoriasis has a distinctive look once you know what to check. The plaques are well demarcated, stopping abruptly at a clear border rather than fading out, and carry adherent silvery-white scale that leaves pinpoint bleeding if picked off. Distribution favours extensor surfaces — the outsides of elbows and knees — along with the scalp, the lower back and the cleft between the buttocks, and the navel. It is usually symmetrical. Itch is present in most people but less dominant than in eczema, and soreness or cracking is often the bigger complaint. The single most useful confirming feature sits at your fingertips: nail pitting, oil-drop discolouration or separation of the nail from its bed occurs in a large share of people with psoriasis and rarely accompanies its look-alikes. Two more clues: new plaques appearing along a scratch or scar, which is the Koebner phenomenon, and a family history. Diagnosis is clinical, with biopsy reserved for genuine uncertainty.

An immune system attacking the skin — T cells driving interleukin-17 and interleukin-23 signalling, on an inherited genetic background, triggered by environment.

Psoriasis is an immune-mediated inflammatory disease rather than a skin problem that happens to look inflamed. Specific immune cells become activated and release cytokines, particularly interleukin-17, interleukin-23 and tumour necrosis factor, which drive keratinocytes to multiply far faster than normal — skin cells that should take about a month to reach the surface do so in days, piling up as the characteristic scale — while recruiting more inflammation and new blood vessels, which is why plaques are red and bleed when scale is removed. That cytokine map is not academic: it is precisely why modern biologics targeting IL-17 and IL-23 work as well as they do. Genetics supply the susceptibility, with more than sixty associated gene regions identified and a strong family history in many people. Environment supplies the trigger — streptococcal infection, skin injury, certain medications, smoking, obesity, alcohol and stress are the well-documented ones. Nothing in that list is a personal failing, and nothing about hygiene or diet causes psoriasis.

No. It is an immune condition, not an infection — nothing about it transmits by touch, sharing a pool, or any other route.

Psoriasis cannot be caught or passed on, and the belief that it can is the source of most of the social damage the condition does. It arises from an immune system attacking a person's own skin; there is no organism to transmit. Yet people with visible plaques are still asked to leave swimming pools, refused treatment in salons and barbers, and avoided socially — surveys of people with psoriasis consistently document this, and it is a significant contributor to the psychological burden the condition carries. It is worth being able to say plainly that psoriasis is not contagious, and worth knowing that in many jurisdictions refusing a service on that basis may amount to unlawful discrimination against a long-term health condition. What does spread, in a sense that gets confused with contagion, is psoriasis onto your own injured skin — the Koebner phenomenon, where new plaques form at sites of scratches, tattoos or surgery. That is your immune system responding to injury, not infection moving anywhere.

No. It carries a substantial risk of psoriatic arthritis, roughly doubled cardiovascular risk, and high rates of depression — the skin is the visible part.

Treating psoriasis as an appearance issue is the framing that costs people most, because it delays the things that matter beyond the plaques. Psoriatic arthritis develops in a large minority — estimates commonly run up to around a third — and joint damage that accumulates during a diagnostic delay is irreversible. Cardiovascular and metabolic risk is approximately doubled, sufficient that guidance recommends active screening of blood pressure, lipids, glucose and weight rather than leaving it to chance. Depression and anxiety rates are high, and the association tracks disease impact rather than surface area. There are also links with inflammatory bowel disease, fatty liver disease and chronic kidney disease. What follows practically: severity is not measured by how much skin is involved but by function and impact, so hands, feet, scalp and genitals count heavily despite small area; joint symptoms deserve reporting at every appointment; and general health screening is part of psoriasis care rather than separate from it. Anyone describing this as cosmetic is a decade behind the evidence.

Descale first with a salicylic acid or oil preparation, then apply treatment to the scalp itself rather than the hair, in a format you will actually use.

Scalp psoriasis fails mostly on delivery. Thick adherent scale blocks anything applied over it, and products designed for hair rather than scalp never reach the plaque. The sequence that works: soften and lift scale first, using a salicylic acid preparation, coconut-oil compound ointment or an oil left on for several hours or overnight, then wash it out with a tar or ketoconazole shampoo left in contact for several minutes rather than rinsed immediately. Then apply active treatment directly to the scalp with a nozzle, dropper or foam — a potent topical steroid scalp application, a vitamin D analogue, or the combination products that pair both — parting the hair section by section rather than rubbing it over the top. Formats matter enormously for adherence: foams and solutions are more acceptable than greasy ointments for daytime use, and many people do the messy descaling at weekends. Two extras: scalp psoriasis frequently extends onto the forehead, ears and neck, which needs treating too, and hair loss during a bad phase usually recovers once the scalp settles.

Emollients, salicylic acid to lift scale, and coal tar preparations. They soften and reduce plaques; nothing on the shelf clears moderate psoriasis.

The pharmacy tier in psoriasis is real but narrow, and knowing its limits saves months. Emollients are the foundation — used generously they reduce scale, ease cracking and itching, and improve how well prescribed treatments penetrate. Salicylic acid preparations lift adherent scale, which matters because thick scale physically blocks anything applied on top; urea does similar work. Coal tar has genuine evidence going back decades, in shampoos, bath additives and creams; it smells, stains and is cosmetically unpopular, but it works and remains in guidelines. What the shelf cannot do: clear established plaques, treat nail or joint disease, or address the immune process driving any of it. The prescription tier starts with vitamin D analogues such as calcipotriol, usually combined with a potent steroid, and those are the products that actually clear plaques — they are not available over the counter for good reason. Two practical points: descale first, then apply active treatment, and treat over-the-counter products as the supporting layer rather than the attempt.

When topicals have genuinely failed after eight to twelve weeks, when special sites are involved, or when impact on your life is significant regardless of area.

Escalation criteria are more generous than most people assume, and waiting is common. The usual triggers: topical treatment used correctly for eight to twelve weeks without adequate control; involvement of the scalp, face, hands, feet, nails or genitals, which counts as severe regardless of how little skin is involved; extensive disease by area; any psoriatic arthritis, which changes the treatment choice entirely; and substantial impact on work, sleep, relationships or mood, which is an explicit criterion in guidelines rather than an emotional aside. The next tier is usually phototherapy where accessible, then conventional systemic drugs such as methotrexate or ciclosporin, then biologics — with most funding systems requiring documented failure of prior steps. Two things that delay escalation unnecessarily: not mentioning special-site involvement, particularly genital and scalp, and stoicism on quality-of-life questionnaires. Answer those honestly. Two things that speed it: a clear record of what you have used and for how long, and photographs from a bad period.

The safety record is generally good, with infection risk the main concern. Screening for tuberculosis and hepatitis happens before starting for that reason.

Biologics target specific cytokines rather than suppressing immunity broadly, which is why their safety profile is better than older systemic drugs and why long-term registry data have been broadly reassuring. The main consideration is infection: reactivation of latent tuberculosis and hepatitis B is why screening is mandatory before starting, and serious infections are somewhat more common than in untreated populations though less so than with conventional immunosuppressants. Class-specific points matter. TNF inhibitors carry the most historical data and additional cautions around heart failure and demyelinating disease. IL-17 inhibitors can worsen inflammatory bowel disease and are associated with candida infections. IL-23 inhibitors have a particularly clean profile in the data so far. Live vaccines are avoided while on treatment, so vaccination status is brought up to date beforehand. Malignancy risk has not shown a clear increase in current data. What is often left out of the risk conversation: untreated moderate-to-severe psoriasis carries its own cardiovascular and metabolic risk, so the comparison is not against zero.

Yes, at every review. Up to a third of people with psoriasis develop it, delays of years are common, and joint damage during that delay is permanent.

This is the single most consequential thing on a psoriasis page. Psoriatic arthritis develops in a substantial minority of people with psoriasis, and skin disease precedes joint disease in the large majority — which makes dermatology the ideal place to catch it early, and yet undiagnosed psoriatic arthritis in dermatology clinics runs at roughly fifteen percent, with reported diagnostic delays of years. Damage accumulating in that window does not reverse. Symptoms to report rather than dismiss: joint pain and swelling, morning stiffness lasting more than thirty minutes, a whole finger or toe swollen sausage-like, heel or Achilles pain, lower back pain and stiffness that improves with movement, and fatigue. Nail involvement and scalp disease both raise the odds. Validated screening questionnaires exist and take minutes. If you have any of those symptoms, say so explicitly rather than waiting to be asked, and ask for rheumatology referral — treatment choices change entirely, since several biologics treat both skin and joints while others treat only skin.

There is no single best. IL-23 and IL-17 inhibitors give the highest skin clearance rates; the right choice depends on joints, comorbidities and dosing interval.

Modern biologics fall into classes with different profiles, and choosing among them is a matching exercise rather than a ranking. IL-23 inhibitors deliver high clearance rates with infrequent dosing — often every eight or twelve weeks after loading — and a notably clean safety profile. IL-17 inhibitors work quickly and clear skin very effectively, and also treat psoriatic arthritis, but can worsen inflammatory bowel disease and carry a candida signal. TNF inhibitors have the longest track record, treat joints well, and carry more cautions around heart failure and demyelinating disease. What tips the decision: whether you have psoriatic arthritis, since that narrows the field to agents effective for joints; inflammatory bowel disease, which rules out IL-17 agents; pregnancy plans; how often you want to inject; and, unavoidably, what your health system funds, which frequently determines the sequence more than clinical preference does. Two practical points: ask why a particular agent was chosen for you, and mention any bowel symptoms, joint symptoms or pregnancy plans before the decision rather than after.

By meeting documented criteria: a severity score above a threshold, quality-of-life impact, and failure or intolerance of phototherapy and conventional systemics.

Access turns on documentation rather than on how bad it feels. Most systems require a combination of a validated severity score above a threshold, a quality-of-life measure showing significant impact, and evidence that you have failed, not tolerated, or have a contraindication to standard treatments — usually phototherapy plus at least one conventional systemic such as methotrexate. Some allow faster access for special-site disease or psoriatic arthritis. Three things help. Keep a record of everything tried, with doses and durations, since reconstructing five years of treatment inside one appointment produces a weak application. Attend the assessment during a bad period if you can, because scores are recorded on the day. And complete quality-of-life questionnaires honestly rather than stoically — understating the impact is the commonest reason people fail to qualify, and joint symptoms, sleep loss and work absence all count. If you are told you do not meet criteria, ask precisely which criterion is not met, since that tells you what would need to change.

Methotrexate and acitretin must stop well in advance — acitretin for three years. Certolizumab is the biologic most often chosen in pregnancy.

Plan this well ahead, because two of the common drugs have long lead times. Methotrexate is teratogenic and must be stopped before conception, with the interval advised by your team, and it applies to male partners too in many protocols. Acitretin requires pregnancy avoidance for three years after stopping, which effectively rules it out for anyone planning a family. Ciclosporin is generally considered usable in pregnancy where needed. Among biologics, certolizumab pegol is frequently preferred because its structure means it lacks active placental transfer, and it is commonly recommended as first-line where a biologic is required; other TNF inhibitors are often continued into the second trimester, while ustekinumab and secukinumab are typically stopped when pregnancy is planned. Recent cohort data have been reassuring about biologic exposure overall. Topicals — emollients, mild to moderate steroids, and some others — generally continue. Two practical points: raise pregnancy plans before starting any systemic drug rather than after, and expect psoriasis itself to change, since many improve in pregnancy and flare postpartum.

Violet, grey or dark brown rather than red, often with thicker scale and more extensive involvement — and severity is routinely underestimated as a result.

Plaque psoriasis on richly pigmented skin frequently appears violaceous, grey or dark brown instead of the salmon-pink shown in most textbooks, and the erythema that severity scores lean on is far harder to assess. Scale often appears thicker and more silvery against the darker background. Studies and expert surveys also report more extensive body surface involvement in Black patients than in white patients, alongside lower rates of diagnosis — a combination that points at recognition rather than biology. The practical consequences are two. Severity gets underestimated, both by clinicians using erythema-weighted scores and by patients comparing themselves to reference images that do not resemble their skin, which delays escalation. And the aftermath differs: plaques resolve leaving prominent hyper- or hypopigmented patches that take three to twelve months to fade, and many people do not consider treatment successful until those resolve. What helps: judge by thickness and area rather than colour, photograph in consistent light, and state impact in functional terms that survive translation across skin tones.

Clear skin is the treatment working, not the disease ending. Most people relapse within months of stopping systemic treatment, so maintenance is the plan.

Psoriasis is controlled rather than cured, and stopping treatment when clear is the single commonest route back to where you started. With topicals, the usual approach is stepping down rather than stopping — reducing potent steroid to intermittent use while continuing a vitamin D analogue, with emollients throughout. With systemic treatment the evidence is clearer: most people relapse within months of discontinuation, though a minority stay clear far longer, and the withdrawal of some drugs carries specific risks, notably oral steroids and, less predictably, abrupt cessation after long potent topical use. There are legitimate reasons to stop or pause — pregnancy planning, surgery, infection, side effects, or a considered trial off treatment after prolonged remission — and those are conversations rather than unilateral decisions, because how you stop matters. Two practical points: if you have stopped and relapsed, restarting the same treatment usually works again; and if you are stopping because the regimen is unmanageable, saying so opens the door to a simpler one rather than to none at all.

Yes. Depression and anxiety are substantially more common in psoriasis, and the association tracks impact and itch rather than how much skin is involved.

The psychological burden of psoriasis is well documented and consistently underestimated. Rates of depression and anxiety are markedly higher than in the general population, and studies find the association driven by itch, sleep disruption, visibility and social consequences rather than by body surface area — which is why someone with limited but visible disease can be more affected than someone with widespread plaques under clothing. Add the specific indignities: being stared at, asked to leave pools, refused salon services, and assumed to be contagious. There is also a plausible biological contribution, since the inflammatory cytokines involved in psoriasis are implicated in depression, and some people report mood improving on systemic treatment beyond what clear skin alone would explain. Two things follow. Psychological impact is an explicit criterion in escalation decisions, so saying it plainly at appointments changes the plan rather than sounding self-indulgent. And if low mood has persisted independently of your skin, it deserves its own treatment alongside rather than waiting for clearance.

Because psoriasis roughly doubles cardiovascular and metabolic risk, and guidance recommends active screening rather than leaving it to chance.

Psoriasis is a systemic inflammatory disease, and the same inflammation implicated in the skin is associated with atherosclerosis and metabolic dysfunction. Studies consistently find approximately twice the risk of cardiovascular disease and metabolic syndrome compared with the general population, with the association strongest in more severe disease, and comorbidities including hypertension, dyslipidaemia, diabetes, obesity and fatty liver disease occurring at raised rates. Guidance therefore recommends active screening: blood pressure, fasting glucose or HbA1c, lipids, weight and waist circumference measured regularly, usually annually for moderate-to-severe disease, by a dermatologist or primary care clinician. This is not incidental to psoriasis care; for many people it is the part with the greatest effect on how long they live. What follows practically: ask who is doing these checks, since they fall between specialties and get missed; treat smoking cessation, activity and weight as part of psoriasis management rather than as unrelated lifestyle advice; and note that psoriasis is not included in most standard cardiovascular risk calculators, which may therefore underestimate your risk.